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isations due to adverse events, and other medical resources
(blood transfusions, onerous concomitant medications) for each
regimen to provide total cost per patient. RESULTS: In France,
the total treatment costs per patient by 21 months were 10,957€
for Gem/Cis, 12,512€ for Vin/Cis and 13,268€ for Pac/Car. The
average number of chemotherapy cycles in the clinical trial was
4.02, 4.23, and 3.25 for Gem/Cis, Pac/Carbo and Vin/Cis,
respectively, giving a lower total treatment cost per chemother-
apy cycle for Gem/Cis (2721€) than for Pac/Car (3136€) or
Vin/Cis (3850€). The total cost difference between Gem/Cis and
Pac/Car (2330€) was mainly due to the highest chemotherapy
acquisition costs for Pac/Car, which were not offset by lower
costs elsewhere. The difference in total costs between Gem/Cis
and Vin/Cis (1575€) were due primarily to the higher rate of hos-
pitalisation in the Vin/Cis group. CONCLUSIONS: Gem/Cis
administered as a 3-week cycle incurs lower costs per patient
than a 3-week cycle of Pac/Carbo and a 4-week cycle of Vin/Cis
when other direct costs are considered in addition to chemother-
apy acquisition costs. Notably, hospitalisation costs due to
adverse events are a major cost driver for some chemotherapy
regimens.
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OBJECTIVES: Novel chemotherapy regimens are cost-effective
relative to best supportive care in the treatment of patients 
with advanced non-small cell lung cancer (NSCLC). A recently
published randomised controlled clinical trial demonstrated 
that gemcitabine/cisplatin (Gem/Cis), paclitaxel/carboplatin
(Pac/Carbo) and vinorelbine/cisplatin (Vin/Cis) were equally
effective with regards to overall survival and time to disease pro-
gression in Italian patients with advanced NSCLC. We per-
formed a retrospective economic analysis to compare these three
combination regimens from the perspective of the German health
care system. METHODS: Cost-minimisation and cost-effective-
ness analyses were based on resource use and efﬁcacy data from
the clinical trial of Scagliotti et al. (2002). The following direct
treatment-related costs were identiﬁed for each chemotherapy
regimen: chemotherapy acquisition, drug administration, hospi-
talisations, and other medical resources. Unit costs of medical
resources in Germany were derived from ofﬁcial published
sources. Cost-effectiveness results were calculated by dividing the
mean total treatment cost per patient by the mean number of
extra life-months gained or by the mean number of months free
of disease progression per patient treated. RESULTS: The
average total treatment costs per patient were 15,211€ for
Pac/Carbo, 8738€ for Gem/Cis, and 9721€ for Vin/Cis. The
incremental cost-effectiveness ratio for Pac/Carbo vs Gem/Cis
was 65,000€ per additional life-month gained. Incremental
analysis showed Gem/Cis to dominate Vin/Cis with additional
survival achieved for less cost. CONCLUSIONS: Based on
resource use and efﬁcacy data from the same clinical trial,
Gem/Cis is a cost-effective combination chemotherapy regimen
for the treatment of advanced NSCLC in Germany.
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OBJECTIVES: Platinum-based combination chemotherapy regi-
mens with new agents such as gemcitabine, paclitaxel and
vinorelbine have been investigated for the treatment of non-
small-cell lung cancer (NSCLC), but no speciﬁc regimen has
proven superiority in terms of prolonged survival. Assessing the
costs of treatment and establishing which regimens provide value
for money are important issues for Health Care providers. This
study aimed to compare the mean total treatment costs of three
novel chemotherapy regimens from the perspective of the UK
National Health Service (NHS). METHODS: Resource utilisa-
tion and clinical outcome data were drawn from Scagliotti et al.
(2002), a prospective, randomised, controlled trial of gemc-
itabine/cisplatin (Gem/Cis), paclitaxel/carboplatin (Pac/Carbo)
and vinorelbine/cisplatin (Vin/Cis) in 612 chemotherapy-naïve
patients with locally advanced NSCLC. No statistically signiﬁ-
cant differences were found between the treatment options in
terms of progression-free and overall survival and, accordingly,
a cost-minimisation analysis was conducted. Only direct medical
resource costs were included in the analysis. Costs were com-
pared across four main resource categories: chemotherapy acqui-
sition, drug administration, hospitalisations associated with
adverse events and other medical resources. UK health care unit
costs were derived from published literature and public NHS
sources. RESULTS: Patients treated with Gem/Cis had lower
mean total treatment costs (£6688) than patients treated with
Pac/Carbo (£10,203) or Vin/Cis (£7102). Chemotherapy acqui-
sition was the major cost component for Gem/Cis and Pac/Carbo
patients (51% and 79% of total costs per patient, respectively),
whereas chemotherapy acquisition and hospitalisations
accounted for 31% and 32%, respectively, of the total per-
patient costs of the Vin/Cis regimen. CONCLUSIONS: For treat-
ment of advanced NSCLC in the UK, Gem/Cis is associated 
with lower direct treatment-related costs than Pac/Carbo or
Vin/Cis. This analysis presents evidence that the Gem/Cis regime
provides greater value for money to fund-holders with a limited
budget.
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OBJECTIVES: A prospective randomised controlled Phase III
clinical trial demonstrated that three platinum-based chemother-
apeutic regimens with novel agents—gemcitabine/cisplatin
(Gem/Cis), paclitaxel/carboplatin (Pac/Carbo) and vinorelbine/
cisplatin (Vin/Cis)—had comparable efﬁcacy in chemotherapy-
naive Italian patients with advanced non-small cell lung cancer
(NSCLC): median survival times ranged from 9.5 to 9.9 months
and median time to progression ranged from 4.6 to 5.5 months
(Scagliotti et al. 2002). As part of the Gemzar Retrospective Eco-
nomic Analysis of clinical Trials (GREAT2), we performed a ret-
rospective cost comparison of these three chemotherapeutic
regimens from the perspective of the Italian health care system.
METHODS: The analysis involved costing of chemotherapy and
medical resource utilisation collected prospectively during the
trial published by Scagliotti et al. (2002). Direct costs were com-
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pared from four resource categories: chemotherapy acquisition,
drug administration, hospitalisation associated with adverse
events, and other medical resources. Italian health care unit costs
were obtained from published sources. RESULTS: Lowest treat-
ment costs were incurred by the Gem/Cis group (8092€), fol-
lowed by the Vin/Cis and Pac/Carbo groups (9320€ and 11,203€
respectively). The cost difference between the Gem/Cis and
Pac/Carbo regimens was due to the difference in chemotherapy
acquisition costs (3732€), which offset the increased costs for
drug administration (499€) and other medical resources (524€)
in the Gem/Cis group. The overall per-patient cost saving for
Gem/Cis versus Vin/Cis (1227€) was primarily due to reduced
hospitalisations for adverse events (2223€) despite the increased
acquisition costs for Gem/Cis (1422€). CONCLUSIONS: Based
on data collected during a randomised clinical trial, ﬁrst-line use
of Gem/Cis offers potential cost savings compared to other plat-
inum-based third-generation agent combinations in the treat-
ment of advanced NSCLC in Italy. Since these savings relate
primarily to chemotherapy acquisition and hospitalisation costs
due to adverse events, they are likely to be transferred to the
community setting.
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OBJECTIVE: As the prognosis of non-small cell lung cancer
(NSCLC) patients after ﬁrst and second line treatment remains
poor, new targeted strategies in third-line treatment are of high
interest. This study estimates the cost-effectiveness of geﬁtinib
compared to Best Supportive Care (BSC) in the Dutch health care
setting. METHODS: A Markov model was designed to evaluate
the lifetime clinical and economic outcomes of geﬁtinib treat-
ment and BSC. The model was calibrated using clinical data from
randomized clinical studies, a Delphi panel (n = 10), patient chart
analysis and literature for costs data. The analysis was performed
from a societal perspective for a hypothetical cohort of advanced
NSCLC patients, who have failed two chemotherapy regimens.
Only direct costs related to the treatment of severe adverse
events, radiotherapy, evaluation of disease progression and ter-
minal care were considered. The time horizon related to mor-
tality, estimated the costs from start of therapy until death. Both
costs and effects were discounted at 4% pa. RESULTS: With an
assumed difference in survival of 2.45 months between geﬁtinib
and BSC, the model predicts survival of 0.573 life years (LY) for
BSC and 0.790 LY for geﬁtinib. Total costs related to BSC and
geﬁtinib treatment until death are 8444€ and 15,272€ respec-
tively. The average cost-effectiveness ratio of geﬁtinib is higher
than BSC (19,326€/LY versus 14,745€/LY). The incremental
cost-effectiveness ratio of geﬁtinib compared to BSC is 31,380€
per LYG. Applying the threshold proposed by the Institute for
Medical Technology Assessment for disease with highest burden
(45,000€/QALY), geﬁtinib is cost-effective in 73% of advanced
NSCLC patients compared to BSC in third-line therapy. CON-
CLUSION: In addition to its convenient oral administration, its
favorable tolerability proﬁle, geﬁtinib is cost-effective compared
to not only BSC but also compared to heart or liver transplan-
tations. “Iressa” is a trademark of the AstraZeneca group of
companies.
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OBJECTIVES: To evaluate the costs in Spain of treating
advanced non-small-cell lung cancer (NSCLC) with gemcitabine
plus cisplatin (Gem/Cis) in comparison with other platinum-
based combination chemotherapy regimens, and to compare the
ﬁndings with previously published cost analyses. METHODS: A
retrospective economic analysis was conducted based on medical
resource utilisation in a randomised controlled trial (Scagliotti 
et al. 2002), which found that Gem/Cis demonstrated compara-
ble efﬁcacy to paclitaxel/carboplatin (Pac/Carbo) and vinorel-
bine/cisplatin (Vin/Cis) regimens in 612 patients with advanced
NSCLC. Treatment costs were compared across four main
resource categories: chemotherapy acquisition, drug administra-
tion, hospitalisation episodes, and other medical resources.
Spanish Health Care unit costs were drawn from published lit-
erature and public sources. Results were compared with those
published by Schiller et al. (2004). RESULTS: The mean total
treatment-related costs of Gem/Cis were 5578€ per patient,
which was lower than those seen with Pac/Carbo (11,541€) or
Vin/Cis (6084€). Chemotherapy acquisition was the major cost
driver for Gem/Cis (63% of total costs) and Pac/Carbo (90% of
total costs), but other component costs, especially hospitalisa-
tions, were considerable for the Vin/Cis regimen (36% of total
costs). The total costs per patient are comparable to those
reported for Spain by Schiller et al. (2004) with calculations
based on Comella et al. (2000) (Gem/Cis 4072€; Vin/Cis 4899€)
and Schiller et al. (2002) (Gem/Cis 5082€; Pac/Carbo 840€),
trials employing different dosing schedules. CONCLUSIONS:
Cost-minimisation analyses based on chemotherapy and
resource utilisation in randomised controlled clinical trials
demonstrate that Gem/Cis has lower total treatment costs from
the perspective of the Spanish national health system than
Pac/Carbo and Vin/Cis for the treatment of advanced NSCLC.
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OBJECTIVE: To assess the cost-effectiveness of geﬁtinib
(“Iressa”) compared to BSC in patients with refractory advanced
NSCLC in the UK National Health Service (NHS). METHODS:
A probabilistic model was developed to assess the cost-
effectiveness (and associated uncertainty) of geﬁtinib compared
with BSC in patients with refractory advanced NSCLC in the UK
NHS. Efﬁcacy data were drawn from two independent sources:
data for geﬁtinib were derived from IDEAL II (patients refrac-
tory to platinum and docetaxel) and data for BSC were derived
from a literature review (BSC arm of a randomised controlled
trial in second-line advanced NSCLC). Cost data were collected
from the perspective of the UK NHS. In the absence of a UK
price for geﬁtinib, the pre-approval sales price in France (1950€)
was converted into UK prices (approximately £1300). Resource
utilisation and cost data for geﬁtinib were derived from pub-
